{
  "schemaVersion": 1,
  "organisationId": "O-22ba2fe8db654e6bbbf1ce5c3ee03d47",
  "slug": "disc-medicine-inc",
  "name": "Disc Medicine, Inc.",
  "updatedAt": "2026-10-02T12:13:29.324717Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Disc Medicine, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing medicines for serious hematologic diseases. Its research focuses on pathways involved in red-blood-cell production and function, particularly heme biosynthesis and iron regulation. [P110488206][P56764452] The company’s pipeline includes bitopertin for erythropoietic porphyrias, selcodebart for anemia associated with myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle-cell disease. [P144736002][P144736004][P144736008]\n\nDisc’s stated purpose is to advance treatments targeting fundamental pathways in red-blood-cell biology. It is headquartered in Watertown, Massachusetts, and its clinical research has included sites in the United States and Australia; it also holds worldwide rights to bitopertin. [P56764452][P10799117][P70981703] At December 31, 2025, the company reported 155 full-time employees, reflecting its research-focused, clinical-stage scale. [P20307097]\n[P110488206][P56764452][P144736002][P144736004][P144736008][P10799117][P70981703][P20307097]",
      "updatedAt": "2026-10-02T12:13:29.324717Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Disc Medicine’s product portfolio consists of investigational therapies for hematologic and iron-related disorders. **Bitopertin** is an oral, selective glycine transporter 1 (GlyT1) inhibitor being developed for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), conditions associated with excess protoporphyrin IX. Its Phase 3 APOLLO trial completed enrollment in 2026; the FDA issued a complete response letter on the accelerated-approval application in February 2026. [P144773225][P144773226][P144773227]\n\n**Selcodebart (DISC-0974)** is an antibody designed to suppress hepcidin and increase serum iron, under investigation for anemia associated with myelofibrosis and inflammatory bowel disease. **DISC-3405**, an antibody targeting TMPRSS6, is designed to increase hepcidin and reduce serum iron; it is being studied in polycythemia vera and sickle cell disease. **DISC-0998** is a preclinical antibody targeting hemojuvelin, designed to suppress hepcidin and increase serum iron, with development directed at anemia associated with inflammatory disease. [P144773229][P144773231][P144773232]\n\nThe company reports no marketed products or product-sales mix; its disclosed program-level research and development expenses are not product revenue or sales percentages. No separate service offering is described. [P144773223][P144773646][T16559542]\n[P144773225][P144773226][P144773227][P144773229][P144773231][P144773232][P144773223][P144773646][T16559542]",
      "updatedAt": "2026-10-02T12:13:29.324717Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Disc Medicine’s principal executive office is at 321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472, and the company describes itself as headquartered in the greater Boston area. [T16559520][P144774058]\n\nIts disclosed clinical-trial geographies include Australia for BEACON; Australia and the United States for HELIOS; and Canada, Europe, Australia, and the United States for APOLLO. [P144773591] The company reports no product candidates with marketing approval, and the reviewed filings do not provide revenue by geography, sales regions, or employee distribution by location. [P144773605]\n[T16559520][P144774058][P144773591][P144773605]",
      "updatedAt": "2026-10-02T12:13:29.324717Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Disc Medicine reports one operating and reportable segment, rather than separate reportable segments by product or disease area. Its chief operating decision maker reviews consolidated financial information to allocate resources and assess performance; accordingly, the company does not disclose percentage contributions by individual program or portfolio. [P144773204][P144773205]\n\nWithin that single segment, the company groups its pipeline around heme biosynthesis modulation and iron homeostasis. The heme-biosynthesis program bitopertin targets erythropoietic porphyrias, initially erythropoietic protoporphyria and X-linked protoporphyria. Iron-homeostasis programs include selcodebart for anemia associated with myelofibrosis and inflammatory bowel disease, DISC-3405 for polycythemia vera, sickle cell disease and other hematologic disorders, and preclinical DISC-0998 for anemia associated with inflammatory diseases. [P144773223][P144773225][P144773229][P144773231][P144773232] Disc Medicine states that it has never commercialized a product candidate, so revenue contributions by these programs are not quantifiable. [P144773646]\n[P144773204][P144773205][P144773223][P144773225][P144773229][P144773231][P144773232][P144773646]",
      "updatedAt": "2026-10-02T12:13:29.324717Z"
    },
    {
      "type": "HISTORY",
      "text": "Disc Medicine was founded in 2017, seeded by Atlas Venture, with Brian MacDonald as founder. In 2019, it secured a $50 million Series A financing and licensed worldwide rights to AbbVie’s hemojuvelin-antagonist antibodies, establishing the DISC-0974 program. [https://www.prnewswire.com/news-releases/disc-medicine-completes-50-million-series-a-financing-led-by-novo-holdings-as-to-advance-new-therapies-addressing-ineffective-red-blood-cell-production-300946714.html] [https://www.sec.gov/Archives/edgar/data/1816736/000114036122032239/ny20005172x1_ex10-3.htm]\n\nIn 2021, Disc licensed bitopertin from Roche and began clinical testing of DISC-0974. In 2022, it merged with public company Gemini Therapeutics in a transaction that made Disc Medicine, Inc. the listed parent; the renamed company began trading on Nasdaq under the symbol IRON. [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-expands-hematology-pipeline-worldwide-licensing] [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-initiates-phase-1-clinical-study-disc-0974-first] [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-completion-merger-gemini-therapeutics]\n\nIn 2023, Disc licensed additional antibody programs from Mabwell, later including DISC-3405, and raised approximately $157.8 million in a public offering. The company reported positive Phase 2 findings for bitopertin in 2023 and 2024; founder Brian MacDonald’s retirement was announced in December 2023. In 2025, Disc submitted a U.S. new drug application for bitopertin for erythropoietic protoporphyria and initiated the Phase 3 APOLLO trial. [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-exclusive-licensing-agreement-mabwell] [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-reports-second-quarter-2023-financial-results-and] [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-retirement-brian-macdonald-mb-chb-phd] [https://ir.discmedicine.com/news-releases/news-release-details/disc-reports-topline-results-phase-2-aurora-study-bitopertin] [https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-submission-new-drug-application-nda-us]",
      "updatedAt": "2026-10-02T12:13:29.324717Z"
    }
  ],
  "sources": [
    {
      "id": "P110488206",
      "href": "https://app.finbar.com/go?id=P110488206",
      "label": "Disc Medicine, Inc. — Full financial report (2025 Y)",
      "documentId": "D-63e40af748a346ae998545daf7c5ea97"
    },
    {
      "id": "P56764452",
      "href": "https://app.finbar.com/go?id=P56764452",
      "label": "Disc Medicine, Inc. — Full financial report (2025 Y)",
      "documentId": "D-63e40af748a346ae998545daf7c5ea97"
    },
    {
      "id": "P144736002",
      "href": "https://app.finbar.com/go?id=P144736002",
      "label": "Disc Medicine, Inc. — Press release (2026 Q 2)",
      "documentId": "D-f4a89c51165d4a6fa6de703bd23f01a5"
    },
    {
      "id": "P144736004",
      "href": "https://app.finbar.com/go?id=P144736004",
      "label": "Disc Medicine, Inc. — Press release (2026 Q 2)",
      "documentId": "D-f4a89c51165d4a6fa6de703bd23f01a5"
    },
    {
      "id": "P144736008",
      "href": "https://app.finbar.com/go?id=P144736008",
      "label": "Disc Medicine, Inc. — Press release (2026 Q 2)",
      "documentId": "D-f4a89c51165d4a6fa6de703bd23f01a5"
    },
    {
      "id": "P10799117",
      "href": "https://app.finbar.com/go?id=P10799117",
      "label": "Disc Medicine, Inc. — Full financial report (2025 Y)",
      "documentId": "D-63e40af748a346ae998545daf7c5ea97"
    },
    {
      "id": "P70981703",
      "href": "https://app.finbar.com/go?id=P70981703",
      "label": "Disc Medicine, Inc. — Full financial report (2025 Y)",
      "documentId": "D-63e40af748a346ae998545daf7c5ea97"
    },
    {
      "id": "P20307097",
      "href": "https://app.finbar.com/go?id=P20307097",
      "label": "Disc Medicine, Inc. — Full financial report (2025 Y)",
      "documentId": "D-63e40af748a346ae998545daf7c5ea97"
    },
    {
      "id": "P144773225",
      "href": "https://app.finbar.com/go?id=P144773225",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773226",
      "href": "https://app.finbar.com/go?id=P144773226",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773227",
      "href": "https://app.finbar.com/go?id=P144773227",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773229",
      "href": "https://app.finbar.com/go?id=P144773229",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773231",
      "href": "https://app.finbar.com/go?id=P144773231",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773232",
      "href": "https://app.finbar.com/go?id=P144773232",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773223",
      "href": "https://app.finbar.com/go?id=P144773223",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773646",
      "href": "https://app.finbar.com/go?id=P144773646",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "T16559542",
      "href": "https://app.finbar.com/go?id=T16559542",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "T16559520",
      "href": "https://app.finbar.com/go?id=T16559520",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144774058",
      "href": "https://app.finbar.com/go?id=P144774058",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773591",
      "href": "https://app.finbar.com/go?id=P144773591",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773605",
      "href": "https://app.finbar.com/go?id=P144773605",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773204",
      "href": "https://app.finbar.com/go?id=P144773204",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "P144773205",
      "href": "https://app.finbar.com/go?id=P144773205",
      "label": "Disc Medicine, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-867f8cd6e0e149259074680f6468b30a"
    },
    {
      "id": "https://www.prnewswire.com/news-releases/disc-medicine-completes-50-million-series-a-financing-led-by-novo-holdings-as-to-advance-new-therapies-addressing-ineffective-red-blood-cell-production-300946714.html",
      "href": "https://www.prnewswire.com/news-releases/disc-medicine-completes-50-million-series-a-financing-led-by-novo-holdings-as-to-advance-new-therapies-addressing-ineffective-red-blood-cell-production-300946714.html",
      "label": "www.prnewswire.com"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1816736/000114036122032239/ny20005172x1_ex10-3.htm",
      "href": "https://www.sec.gov/Archives/edgar/data/1816736/000114036122032239/ny20005172x1_ex10-3.htm",
      "label": "www.sec.gov"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-expands-hematology-pipeline-worldwide-licensing",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-expands-hematology-pipeline-worldwide-licensing",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-initiates-phase-1-clinical-study-disc-0974-first",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-initiates-phase-1-clinical-study-disc-0974-first",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-completion-merger-gemini-therapeutics",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-completion-merger-gemini-therapeutics",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-exclusive-licensing-agreement-mabwell",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-exclusive-licensing-agreement-mabwell",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-reports-second-quarter-2023-financial-results-and",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-reports-second-quarter-2023-financial-results-and",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-retirement-brian-macdonald-mb-chb-phd",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-retirement-brian-macdonald-mb-chb-phd",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-reports-topline-results-phase-2-aurora-study-bitopertin",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-reports-topline-results-phase-2-aurora-study-bitopertin",
      "label": "ir.discmedicine.com"
    },
    {
      "id": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-submission-new-drug-application-nda-us",
      "href": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-submission-new-drug-application-nda-us",
      "label": "ir.discmedicine.com"
    }
  ]
}